"{\n \"business_address\": \"CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, DUBLIN, IRELAND D17 E400\", \n \"business_phone_no\": \"(216) 523-5000\", \n \"ceo\": \"Brenton L. Saunders\", \n \"cik\": \"0001578845\", \n \"company_url\": \"www.allergan.com\", \n \"employees\": 31200, \n \"entity_legal_form\": \"INCORPORATED\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"PO Box 19534\", \n \"hq_address2\": null, \n \"hq_address_city\": \"Irvine\", \n \"hq_address_postal_code\": \"92623\", \n \"hq_country\": \"Ireland\", \n \"hq_state\": \"California\", \n \"inc_country\": \"Ireland\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Drugs - Generic\", \n \"latest_filing_date\": \"2017-08-09\", \n \"legal_name\": \"Allergan plc\", \n \"lei\": \"6T6CAG8O6TSUTMO6BA21\", \n \"long_description\": \"Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.\", \n \"mailing_address\": \"CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, DUBLIN, IRELAND D17 E400\", \n \"name\": \"Allergan plc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000FH8PX5\", \n   \"composite_figi_ticker\": \"AGN:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000FH8PX5\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"AGN:US\", \n   \"figi_uniqueid\": \"EQ0010777800001000\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"AGN\"\n  }, \n  {\n   \"composite_figi\": null, \n   \"composite_figi_ticker\": \"AGN$A:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": null, \n   \"figi_exch_cntry\": null, \n   \"figi_ticker\": \"AGN$A:UN\", \n   \"figi_uniqueid\": null, \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": null, \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"ALLERGAN PLC. 5.50% MANDATORY CONVERTIBLE PREFERRED SHARES, SERIES A\", \n   \"security_type\": \"Preferred Stock\", \n   \"share_class_figi\": null, \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"AGN$A\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000F6DQV3\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"A60:GM\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000F6DPN4\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"A60:GD\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000F6DNR5\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"A60:GR\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-06-22\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000F6DP18\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"A60:GF\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-05-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000F6DRF9\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"A60:GB\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAM\", \n   \"figi\": \"BBG000F6DTH3\", \n   \"figi_exch_cntry\": \"GH\", \n   \"figi_ticker\": \"A60:GH\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAM\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"HAM\", \n   \"ticker\": \"A60\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F6DNR5\", \n   \"composite_figi_ticker\": \"A60:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000F6DQH9\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"A60:GS\", \n   \"figi_uniqueid\": \"EQ0010777800001001\", \n   \"last_crsp_adj_date\": \"2017-08-16\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"ALLERGAN PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S9KLP1\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"A60\"\n  }\n ], \n \"short_description\": \"Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland.\", \n \"sic\": 2834, \n \"standardized_active\": false, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"AGN\"\n}"